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Abstract
 
Phenotype analysis of female mice lacking androgen receptor (AR) deficient (
 
AR
 
 
 
/
 
 
 
) indicates
that the development of mammary glands is retarded with reduced ductal branching in the pre-
pubertal stages, and fewer Cap cells in the terminal end buds, as well as decreased lobuloalveolar
development in adult females, and fewer milk-producing alveoli in the lactating glands. The
defective development of 
 
AR
 
 
 
/
 
 
 
 mammary glands involves the defects of insulin-like growth
factor I–insulin-like growth factor I receptor and mitogen-activated protein kinase (MAPK)
signals as well as estrogen receptor (ER) activity. Similar growth retardation and defects in
growth factor–mediated Ras/Raf/MAPK cascade and ER signaling are also found in 
 
AR
 
 
 
/
 
 
 
MCF7 breast cancer cells. The restoration assays show that AR NH
 
2
 
-terminal/DNA-binding
domain, but not the ligand-binding domain, is essential for normal MAPK function in MCF7
cells, and an AR mutant (R608K), found in male breast cancer, is associated with the excessive
activation of MAPK. Together, our data provide the first in vivo evidence showing that AR-
mediated MAPK and ER activation may play important roles for mammary gland development
and MCF7 breast cancer cell proliferation.
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Introduction
 
The roles of androgen receptor (AR; reference 1), a tran-
scriptional factor that belongs to the nuclear receptor super-
family (2), in female organs remains unclear. The lack of
clarity could be due to the lack of in vivo models because
male mice lacking functional AR are infertile; thus, they
are unable to generate female AR knockout (
 
AR
 
 
 
/
 
 
 
) off-
spring. Epidemiological analyses indicated some positive
correlation between testosterone concentration and breast
cancer incidence, although it is debatable that testosterone
effects on breast cancer progression could also result from
conversion to 17
 
 
 
-estradiol (E2) via aromatization in periph-
eral tissues (3, 4). However, other papers also suggested that
androgens could negatively regulate the growth of mammary
epithelial and breast cancer cells (5–7). AR is expressed in
normal breast cells, and up to 85% of breast tumors are AR
positive (8–10). Also, 25–82% of metastatic breast tumors,
which are estrogen receptor (ER) and progesterone (P) recep-
tor (PR) negative, still express a significant amount of AR
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, heregulin-
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fered saline; TEB, terminal end bud; UTR, untranslated region. 
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(9, 11). However, the mechanisms by which AR influences
breast cancer progression and mammary gland development
remain unclear. To answer these long-term puzzles and to
dissect the molecular mechanism of AR in breast cells, we
applied different strategies to knock out the AR gene in fe-
male mice and breast cancer MCF7 cells. Our results dem-
onstrate that AR plays an important role in the mammary
gland development and breast cancer cell growth.
 
Materials and Methods
 
Generation of Female AR
 
 
 
/
 
 
 
 Mice. 
 
Construction of targeting
vectors and generation of the chimera founder mice have been
described previously (12). The strain of the mosaic founder was
C57BL/6-129/SEVE. 
 
 
 
-Actin is a housekeeping gene and is uni-
versally expressed in every tissue; therefore, the 
 
 
 
-actin pro-
moter-driven Cre (ACTB-Cre) will express and delete the floxed
AR fragment in all the cells. The mating strategy is illustrated in
brief in Fig. 1. The female 
 
AR
 
 
 
/
 
 
 
 mice were genotyped by
PCR, rather than by Southern blot analysis, as described in the
figure legend and previously (12).
 
Animal, Tissue Collection, and Real-time RT-PCR. 
 
All animal
experimentation was conducted in accordance with accepted stan-
dards of humane animal care. Tissues were fixed in buffered neutral
formalin for 24 h. Fresh mammary gland tissues were frozen and
stored in liquid nitrogen before RNA extraction. 3 
 
 
 
g of total
RNA was reverse transcribed and subjected to real-time PCR using
iCycle (Bio-Rad Laboratories), and the formulas used were de-
scribed previously (13). Primer pair sequences were designed by
Beacon Designer II software (Bio-Rad Laboratories). Primer pair
sequences used for studying gene expression change are as follows:
mouse PR, 5
 
 
 
-CAGATTCAGAAGCCAGCCAGAG-3
 
 
 
 and
5
 
 
 
-CCACAGGTAAGCACGCCATAG-3
 
 
 
; mouse hepatocyte
growth factor (HGF), 5
 
 
 
-AGGTACGCTACGAAGTCTGTG-3
 
 
 
and 5
 
 
 
-GGTGTGGTGTCTGCTGGTC-3
 
 
 
; mouse estrogen-
responsive finger protein (Efp), 5
 
 
 
-ACCGCCTCTGTGTCTGA-
TGG-3
 
 
 
 and 5
 
 
 
-GCCTACGCCGCAGAAGTTG-3
 
 
 
; mouse IGF-1,
5
 
 
 
-TGCTCTTCAGTTCGTGTG-3
 
 
 
 and 5
 
 
 
-ACATCTCCAGT-
CTCCTCAG-3
 
 
 
; mouse IGF-1R, 5
 
 
 
-GCCGACGAGTGGAG-
AAATC-3
 
 
 
 and 5
 
 
 
-CTTGGAGATGAGCAGGATGTG-3
 
 
 
; human
Ki67, 5
 
 
 
-ATCGTCCCAGGTGGAAGAGTT-3
 
 
 
 and 5
 
 
 
-ATAG-
TAACCAGGCGTCTCGTGG-3
 
 
 
; human c-myc, 5
 
 
 
-CAGCTG-
CTTAGACGCTGGATTT-3
 
 
 
 and 5
 
 
 
-ACCGAGTCGTAGTC-
GAGGTCAT-3
 
 
 
; and human Bcl-2, 5
 
 
 
-CATGTGTGTGGAG-
AGCGTCAA-3
 
 
 
 and 5
 
 
 
-GCCGGTTCAGGTACTCAGT-3
 
 
 
.
 
 
 
-Actin was used as an internal control.
 
Whole-mount Staining of Mammary Glands. 
 
Whole mammary
glands were spread on glass slides, fixed overnight in Carnoy’s so-
lution (Ethanol/CHCl
 
3
 
/acetic acid, 6:3:1), sequentially rehy-
drated by 100, 95, 70, and 50% ethanol and tap water, and stained
in carmine red solution overnight until the whole gland became
red. After staining, the tissue slides were dehydrated, cleared with
xylene, and mounted.
 
Immunohistochemistry and Bromodeoxyuridine (BrdU) Staining.
 
Mammary glands were fixed overnight in buffered neutral formalin
(VWR Scientific Products) at room temperature. The tissues were
dehydrated by passing through 70, 85, 95, and 100% ethanol,
cleared in xylene and 1:1 xylene/paraffin for 45 min, and embed-
ded in paraffin. Tissue sections were cut at a 5–7-
 
 
 
m thickness and
mounted onto Probe-On Plus charged slides (Fisher Scientific).
For immunohistochemistry, sections were heated at 55
 
 
 
C for
at least 2 h, deparaffinized in xylene, rehydrated, and washed in
Tris-buffered saline (TBS), pH 8.0. For antigen retrieval, slides
were microwaved in 0.01 M sodium citrate, pH 6.0, immersed
with 1% hydrogen peroxide in methanol for 30 min, and blocked
with 20% normal goat serum in TBS for 60 min. After washing with
PBS, sections were incubated for 90 min in different antibodies
diluted 1:200 to 1:500 in TBS containing 1% BSA, followed by
goat anti–rabbit biotinylated secondary antibody diluted 1:300 in
TBS containing 1% BSA. Sections were incubated with avidin-
biotin–peroxidase complex solution for 30 min, followed by
development with diaminobenzidine peroxidase substrate kit
(Vector Laboratories) for 5 min. Slides were counterstained
with hematoxylin for 30 s, dehydrated, cleaned in xylene, and
mounted. Primary antibody was replaced with normal rabbit IgG
or 1% BSA in TBS for negative controls. Both of anti-phospho–
mitogen-activated protein kinase (MAPK) and total MAPK anti-
bodies were obtained from Cell Signaling Technology. BrdU la-
beling reagents and BrdU staining kit were purchased from
Zymed Laboratories.
 
Steroid Hormone RIA. 
 
For characterization of hormonal pro-
files, sera were collected by the intracardiac method from 
 
AR
 
 
 
/
 
 
 
and 
 
AR
 
 
 
/
 
 
 
 mice under ketamine and xylazine anesthesia (Sigma-
Aldrich). Concentrations of E2 and P were determined using
Coat-a-Count kits (Diagnostic Instruments).
 
Construction of the AR Targeting Vector and Generation of AR
 
 
 
/
 
 
 
MCF7 Cells. 
 
The targeting vector for generating 
 
AR
 
 
 
/
 
 
 
MCF7 cells was constructed by replacing the SmaI–KpnI seg-
ments within the AR exon 1 with a promoterless neomycin cas-
sette and inserting two flanking sequences, 5
 
 
 
 extending 1.1 kb
into the human AR 5
 
 
 
 untranslated region (UTR) and 3
 
 
 
 extend-
ing 6.2 kb into the AR intron 1, on a pGEM-T easy vector
(Promega). This promoterless neomycin cassette, containing a
termination codon and a polyadenylation signal, was inserted in
frame with AR ATG start codon. The flanking homologous se-
quences were generated by PCR using the genomic DNA from
human LN Cap cells as a template. For generation of 
 
AR
 
 
 
/
 
 
 
MCF7 cells, parental MCF7 cells were transfected with the AatII-
linearized AR targeting vector using SuperFect (QIAGEN) and
selected with 400 
 
 
 
g/ml neomycin. The genotypes of surviving
clones were screened by Southern blot analyses. The heterozy-
gous clones (
 
AR
 
 
 
/
 
 
 
) were picked up and subjected to the second
gene targeting experiment using the same targeting vector.
Clones were selected with a higher concentration of neomycin
(1.25 mg/ml). The genotypes of surviving clones were screened
again by Southern blot analyses.
 
Plasmids. 
 
GAL4-Elk1, constitutively activated MEK1 (MEK-
CA), Ras (Ras-CA), Raf (Raf-CA), dominant-negative Ras (Ras-
DN) and Raf (Raf-DN), and MEK1 phosphatase CL-100 plasmids
were provided by K.-L. Guan (University of Michigan Medical
School, Ann Arbor, MI; reference 14). Constitutively activated Rac
plasmid was a gift from J. Chernoff (Fox Chase Cancer Center, Phil-
adelphia, PA; reference 15). The reporter genes (ARE)4-luciferase
(Luc), ERE-Luc, and pG5-Luc used for monitoring AR, ER, and
GAL4-Elk transactivation, respectively, were described previously
(16). FLAG-tagged AR deletion mutant expression plasmids were
constructed by inserting PCR-generated AR cDNA fragments into
pCDNA3 vector (Invitrogen) containing FLAG tag. The natural
promoter–driven (np)-AR plasmid was constructed by inserting 3.6
kb hAR promoter, the entire hAR 5
 
 
 
-UTR, full-length AR cDNA,
and 310-bp 3
 
 
 
-UTRs followed by 280-bp bovine GH poly(A) sig-
nals into pBlueScript sk(
 
 
 
) vector (Stratagene). The AR small inter-
fering RNA (siRNA) expression vector that expresses an siRNA-
targeting AR in mammalian cells was constructed by digesting and
inserting a double-strained polynucleotide 5
 
 
 
-GTCGGGCCCT- 
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ATCCCAGTCCCACTTGCTCGAGCAAGTGGGACTGGGA-
TAGGGCTTTTTGAATTCGC-3
 
 
 
 into the ApaI–EcoRI site of a
DNA-based vector BS/U6 (17).
 
MTT Growth Assays. 
 
10
 
4
 
 cells seeded on 24-well plates were
cultured with RPMI 1640 supplemented with 10% of charcoal
dextran–stripped (CDS)–FBS for treatment with 0.1 nM E2 or
0.2% of heat-inactivated (HI)–FBS) for treatment with 100 ng/ml
IGF-1 or 50 ng/ml epidermal growth factor (EGF). The cells
were collected at indicated days for MTT assay according to the
manufacturer’s instructions (Sigma-Aldrich).
 
Soft-agar Colony Formation Assay. 
 
2 
 
 
 
 10
 
4
 
 cells suspended in
0.4% low melting agarose (FMC Corp.) were layered on top of 1
ml of 0.8% agarose in 6-well culture plates. Cells were incubated
with 1 ml RPMI 1640 supplemented with 10% CDS-FBS for
treatment with 0.1 nM E2 or 0.2% HI-FBS for treatment with
100 ng/ml heregulin-
 
 
 
 (HRG-
 
 
 
). After 4 wk of incubation, the
colonies were visualized by incubating with 1 mg/ml INT
(Sigma-Aldrich) for 24 h and counted with VersaDoc Imaging
System (Bio-Rad Laboratories).
 
Reporter Gene Assays. 
 
Cells were plated in 96-well plates and
plasmids at 0.5 
 
 
 
g per well were transfected into cells using Su-
perFect (QIAGEN). The medium was changed 2 h after transfec-
tion, and cells were cultured in media containing 10% CDS-FBS
or 0.2% HI-FBS for 16 h, followed by treatment with 50 ng/ml
EGF, 100 ng/ml IGF-1, 100 ng/ml HRG-
 
 
 
, 0.1 nM E2, or 1
nM DHT for another 16 h. 5 ng pRL-TK per well was used as
internal control. Cells were harvested, and the Luc activity was
analyzed using Dual-Luc Reporter Assay System (Promega).
 
Western Blots. 
 
Cells were lysed with radioimmunoprecipita-
tion assay buffer containing 0.5% NP-40 and Western blotted with
anti-AR (NH-27), anti-ER, antiactin, anti–green fluorescent pro-
tein (GFP; Santa Cruz Biotechnology, Inc.), anti–total MAPK, and
anti–phospho-MAPK (Cell Signaling Technology).
 
Statistical Analysis. 
 
All data were analyzed by one-way analy-
sis of variance using minitab statistical software (State College).
Mean separation was accomplished using Fisher’s pairwise com-
parison. Differences were considered significant at P 
 
  
 
0.05.
 
Results
 
Generation and Phenotype of Female AR
 
 
 
/
 
 
 
 Mice. 
 
Us-
ing a Cre-lox conditional knockout strategy by mating the
floxed AR male mice with 
 
AR /  ACTB Cre  females,
we were able to generate female AR /  mice, genotyped
as AR    ACTB Cre  (Fig. 1, A and B). Adult female
mice with homologous deletion of AR appear healthy and
develop normal external genitalia. Gross anatomical exam-
ination did not reveal obvious differences in the morphol-
ogy of most organs between the AR /  and AR /  litter-
mates. The body weights are similar between the AR / 
and AR /  mice, but the thymus of female AR /  mice is
Figure 1. The generation and charac-
terization of immature female AR / 
mice. (A) Gene targeting strategies. To
generate female AR /  mice, a Cre-lox
strategy for conditional knockout was
applied. The Cre-lox system uses the
expression of P1 phage Cre recombinase
to catalyze the excision of DNA located
between flanking lox sites. (B) Breeding
strategy of female AR /  mice and
genotyping of female AR /  mice. Using
the Cre-lox strategy, the targeted exon
2 of AR is not disrupted but floxed in
the male mice. X and RI represent
XbaI and EcoRI restriction enzyme
sites, respectively. Thus, the AR func-
tions normally in male mice, which can
be bred with female AR /  ACTB Cre 
mice and, thereby, generate homozygous
female AR /  mice. For examining the
X chromosome with floxed AR, primers
select and 2-3 are used. Select is located
in the intron 1 with sequence 5 -GT-
TGATACCTTAACCTCTGC-3 . 2-3
is the 3  end primer located in the exon
2 with the sequence 5 -CTTCAGCG-
GCTCTTTTGAAG-3 . This pair of
primers will amplify a product with
 510 bp for floxed AR and  460 bp
for wt AR. For examining the AR
knockout locus, primers select and 2-9
were used. 2-9 is located in intron 2
with the sequence 5 -CTTACATGTACTGTGAGAGG-3 . The PCR product size from this pair of primers would be  270 bp for AR knockout
allele and  600 bp for wt AR allele. The expression of Cre and internal control IL-2 was also confirmed by PCR genotyping. (C) The defects in the
ductal development of mammary gland in immature female AR /  mice. Whole breast mounts from 4-wk-old female AR /  mice show lessened
extension of mammary ducts, as compared with age-matched AR /  mice. (D) The decreases in the percentage of BrdU-positive staining (brown) are
observed in both 4- and 6-wk-old AR /  mice. (E) Statistic analyses of the distance of ductal extension in female AR /  and AR /  mice (left). Statistic
analyses of BrdU staining signal in female AR /  and AR /  mice (right, n   5 for each group). (F) The number of Cap cells (arrows) in TEB of AR / 
mice is less than that in the AR /  mice.Androgen Receptor Roles in Mammary Glands 1902
bigger than that of female AR /  or AR /  mice. Several
estrogen target organs, including mammary gland, ovary,
oviduct, and uterus, were collected from 4-, 6-, and 12-
wk-old mice. The weights of these organs are 15–23% less
in female AR /  mice as compared with their age-
matched littermates.
Defects in Mammary Gland Development in Prepubertal and
Pubertal Stages in Female AR /  Mice.  First, we compared
the morphology of mammary glands between immature
(4- and 6-wk old) virgin AR /  and AR /  mice. By the
fourth to sixth week, the ductal system has  30–50% less
extension in female AR /  mice with reduced numbers
and size of the terminal end buds (TEBs; Fig. 1, C and E).
BrdU staining also revealed a 50% lower proliferation of
AR    mammary glands, as compared with that of AR / 
mice (Fig. 1, D and E). The number of Cap cells (18),
which are responsible for the ductal extension from TEBs,
were also reduced in female AR /  mice (Fig. 1 F). To-
gether, our results indicated that the mammary gland de-
velopment is retarded in prepubertal and pubertal stages in
female AR /  mice.
Reduced Ductal Morphogenesis in the Mammary Glands of the
Mature AR /  Mice.  At maturity (8-, 16-, and 20-wk),
we could see AR /  mammary glands were filled with
large bloated ducts terminating with bloated ends. It is also
obvious that AR /  mammary glands have fewer second-
ary and tertiary ductal branches as compared with age-
matched AR /  and AR /  mice (Fig. 2, A–C). During
the pregnancy stage, the retarded ductal branches in AR   
mice are partially restored, yet compared with AR / 
mice, the AR /  mice mammary glands still have less milk-
producing alveoli (Fig. 2 D). In agreement with these find-
ings, we also observed shrunken ductal spaces in some
AR    mice mammary glands in 16-wk-old or older mice
(Fig. 2 E), and reluctant nursing behavior in some AR / 
mothers. The decreased milk-producing alveoli and
shrunken ductal spaces may result in the lessened capacity
for AR    mice to feed their offspring. In 20-wk-old mice,
we found that mammary glands in some AR    mice un-
derwent degeneration earlier than those of the AR /  mice
(Fig. 2 C). Overall, Fig. 2 demonstrates that the lack of AR
in female mice may retard the mammary gland develop-
ment and affect the capacity of female AR    mice to feed
their offspring.
Defects of MAPK Activity and Insulin-like Growth Factor I
(IGF-I)–IGF-IR Pathway in AR /  Mammary Glands.
Early works indicated that E2/ER, P/PR, and paracrine
growth factors/MAPK signals may contribute to the
growth and development of mammary glands (19–21).
First, we examined the MAPK activity in 4-wk-old mice.
The immunohistochemstaining data show that the overall
phospho-MAPK expression is weaker in the mammary
cells from AR /  mice, as compared with AR /  mice
(Fig. 3 A), although we could observe some ductal mam-
mary cells with intensive phospho-MAPK staining in AR   
mammary glands. The total MAPK protein expression is
similar between AR /  and AR /  mice, as shown in Fig.
3 B. We examined the upstream regulators of MAPK sig-
nals, IGF-I–IGF-IRs. We found that IGF-IR, but not
IGF-I, mRNA expression is reduced by 46% in immature
AR /  mammary glands (Fig. 3 C), suggesting that the
IGF-I–IGF-IR→MAPK signaling pathway may be defec-
tive in female AR /  mice. We investigated the expression
of the downstream target, cyclin D1, in AR    and AR / 
mice using real-time quantitative PCR. The cyclin D1
mRNA expression was significantly reduced in female
AR /  mice (Fig. 3 C). Together, these data showing the
reduction of IGF-IR, cyclin D1, and MAPK activity may
suggest that the defects in the AR→IGF-I–IGF-IR→
MAPK→cyclin D1 signaling pathway might result in the
retarded mammary gland development in female AR / 
mice. This is in agreement with early papers showing that
IGF-I–IGF-IR is an important paracrine growth factor for
mammary gland development (22, 23), and cyclin D1 is a
downstream mediator of growth factor–induced mammary
gland proliferation (24).
Before systematic hormone function that occurs after
puberty, growth factors, such as IGF-I, are the major con-
Figure 2. AR /  mammary glands show the defects of the terminal
branching and alveologenesis during maturity and pregnancy. Whole
breast mounts from 8-, 16-, and 20-wk-old mature and 8-wk-old pregnant
female mice were examined. (A–C) Less secondary and tertiary terminal
branching in AR /  mice, compared with AR /  and AR /  mice. (C)
Early degeneration occurs in AR /  mammary glands in 20-wk-old
mice. (D) The decreased milk-producing lobuloalveolar development in
the 8-wk-old pregnant AR /  mice. (E) Using hematoxylin and eosin
staining, the results indicate that the shrunken ductal space occurs in some
AR /  mammary glands in 16–20-wk-old mice (n   4 for each group). Yeh et al. 1903
tributing factors influencing the mammary gland develop-
ment. IGF-I is a potent mitogen for mammary epithelial
cells, and the ductal development can be stimulated by
IGF-I. The mRNA for IGF-I and IGF-IR is expressed in
mammary stroma and developing TEBs, and targeted dele-
tion of IGF-IR inhibits normal TEB development before
puberty (23). In the present paper, our results indicate that
knock out of AR affects the mammary gland development
before the puberty stage (Figs. 1 and 3), which suggests a
possible disturbance in the growth factor pathway. Indeed,
our results indicated that the reduction of IGF-IR expres-
sion may consequently affect the IGF-I–IGF-1R signal on
development of the mammary gland, including retarded
ductal development, fewer Cap cells in the TEB, and re-
duced BrdU staining and cyclin D1 expression (Figs. 1 and
3). The aforementioned observations concerning the pre-
pubertal AR /  mammary glands suggest a tight association
of AR and growth factor signal in the mammary gland.
Together, our results provide the first in vivo evidence
showing that AR plays a significant role in the prepubertal
as well as adult mammary gland development.
Reduced ER Activity in AR /  Mammary Glands.  Early
analyses indicated that MAPK could also influence ER
function (25), and that cyclin D1 could also be a down-
stream target gene for ER (26). Defects in MAPK and cy-
clin D1 may suggest that ER signals could also be impaired
in the female AR /  mice. Therefore, we ovariectomized
4-wk-old mice, treated them with E2 for 2 d, and har-
vested the mammary glands for the comparison of the ER
activity by examining ER target gene expression between
AR    and AR /  mice. We found that E2-induced Efp
(27) and HGF (28) were down-regulated in female AR / 
mice as compared with AR /  mice (Fig. 3 D). Early
works also indicated that both Efp and HGF were impor-
tant factors for breast cell growth (20, 29). Interestingly, we
found that PR expression in mammary glands was similar
between AR    and AR /  (Fig. 3 D). This finding is con-
sistent with a previous paper showing that PR expression is
E2/ER-independent in 5-wk-old or younger mice (30).
Nevertheless, we found that the serum levels of PR’s
ligand, P, was reduced in 12- to 16-wk-old adult female
AR /  mice (Fig. 3 E), which may result in the reduction
of P/PR activity in mature mice. As the P/PR signal path-
way plays important roles for the tertiary ductal branching
and alveolar development (19), the lower P/PR activity in
AR /  mice may contribute to the retarded branching and
lobuloalveolar formation in the development of mature
stage mammary glands.
The AR /  MCF7 Cells Exhibit Severe Defects in Growth
and Colony Formation.  To further dissect the mecha-
nisms of AR roles in breast tissue at molecular and cellular
levels, we applied the homologous recombination by using
a targeting vector carrying a promoterless neomycin cas-
sette to generate AR-deficient (AR / ) MCF7 cells (Fig. 4
A). Two AR /  MCF7 clones have been successfully ob-
tained, and the targeted loci were confirmed by Southern
blot analysis (Fig. 4 B). In these two homologous clones,
the expression and the ligand-activated transcriptional ac-
tivity of AR were indeed abrogated (Fig. 4, C and D). We
found that AR /  MCF7 cells exhibit a severe impairment
in proliferation when cultured in media containing normal,
steroid-deprived or 10 10 M E2-treated serum (Fig. 4 E).
The soft-agar colony formation assay also showed that the
Figure 3. The reduced MAPK activity and mRNA expression of IGF-
IR, HGF, and Efp in AR /  mammary glands. (A) Reduced MAPK
activities are observed in AR /  mammary glands of 4-wk-old mice.
Mammary glands were stained with anti–phospho-MAPK (p-MAPK)
antibody. The decrease of positive staining (brown) indicates the reduced
MAPK activity in AR /  mammary glands. (B) The similar total MAPK
(T-MAPK) staining results are observed in the mammary glands from 4-wk-
old AR /  and AR /  mice. Adjacent sections were used for p-MAPK
and T-MAPK stainings. (C) The mRNA expression of IGF-IR, but not
IGF-I, is reduced in AR /  mice. Total RNA was extracted from 4-wk-
old AR /  and AR /  mice and quantitated by real-time RT-PCR. Cyclin
D1, a proliferation indicator, is also reduced in mammary glands of female
AR /  mice. (D) The mRNA expressions of two ER target genes, HGF
and Efp, are reduced in AR /  mice. The expression of PR mRNA has
no significant difference (bars 5 vs. 6). Total RNA was extracted from
4-wk-old AR /  and AR /  mice injected with E2 (n   5 for each
group). (E) The serum levels of P were reduced in 12–16-wk-old adult
female AR /  mice.Androgen Receptor Roles in Mammary Glands 1904
colony number of AR /  MCF7 cells was increased in re-
sponse to 10 10 M E2 or 100 ng/ml HRG- , an activator
for the HER2/HER3/HER4 family, whereas the colony
formation of AR /  MCF7 cells was largely reduced (Fig.
4 F). To determine whether abrogating AR expression in
AR /  MCF7 cells can also reduce the cell growth capac-
ity, we used an AR siRNA expression vector that showed
an efficient knock down of AR in cells transfected with
np-AR, a natural AR promoter-driven AR expression
plasmid (Fig. 4 G). We found that the mRNA levels of
Ki67 and c-myc were reduced by 42 and 81%, respectively,
in AR /  MCF7 cells transfected with AR siRNA, com-
pared with the cells transfected with vector alone (Fig. 4
H). Overall, Fig. 4 implies that AR plays an important role
for the growth of MCF7 breast cancer cells.
The Growth Factor–mediated Proliferation and MAPK Acti-
vation Is Impaired in AR /  MCF7.  Next, we examined
whether the loss of AR impairs the growth factor–medi-
ated proliferation and MAPK activation in AR /  MCF7
cells. Treatment of AR /  MCF7 cells with IGF-I, EGF,
or HRG-  could stimulate cell proliferation and activate
GAL4-Elk1, a direct target of MAPK, in a low serum-con-
taining medium (Fig. 5, A and B). In contrast, the growth
factor–stimulated cell proliferation and MAPK activation
were largely impaired in the AR /  MCF7 cells (Fig. 5, A
and B). Using another strategy by transfection of AR
siRNA into AR /  MCF7 cells, we found that suppression
of AR expression could also diminish IGF-I/EGF/HRG-
 –induced MAPK activation (Fig. 5 B). Moreover, the re-
duced transcriptional activity of GAL4-Elk1 in AR / 
MCF7 cells could be rescued by transfection of np-AR
(Fig. 5 C). Interestingly, adding EGF with np-AR could
synergistically enhance the transactivation of GAL4-Elk1 in
AR /  MCF7 cells compared with the cells treated with
EGF alone (Fig. 5 C), suggesting a significant involvement
of AR in the growth factor signaling pathway. Further-
more, the AR-activated GAL4-Elk1 activity could be di-
minished by MAPK phosphatase-1 (CL-100) or a specific
inhibitor U0126, as well as Ras-DN or Raf-DN (Fig. 5 D;
reference 14). Also, the reduction of MAPK activation by
AR siRNA could be recovered by MEK-CA, Ras-CA, or
Raf-CA, but not by Rac-CA (15) or PI3K (Fig. 5 E, p110
catalytic subunit). These results indicate that AR is an im-
portant upstream regulator of the Ras/Raf/MAPK cascade.
The Transcriptional Activity of ER Is Defective in AR / 
MCF7 Cells.  Using an ERE-Luc reporter, we further
compared the ER activity in AR /  and AR /  MCF7
cells. The transcriptional activities of ER were reduced by
58.8, 53.8, and 55.0% in AR /  MCF7 cells in the pres-
ence of E2 at 10 12, 10 10, and 10 8 M, respectively (Fig. 5
F). The reduced transcriptional activity of ER in AR / 
MCF7 cells could be restored by transfection of np-AR
Figure 4. Targeted deletion of
AR gene in MCF7 cells results
in severe defects in cell prolifera-
tion and colony formation. (A)
Schematic diagram of the strategy
of targeting AR genes in MCF7
cells. (B) Genotyping by Southern
blot analysis. Genomic DNA
extracted from neomycin-resistant
clones was digested with XbaI.
The untargeted and targeted loci
produced   9.0-kb and 3.5-kb
bands, respectively. (C) The AR
protein was ablated in AR / 
MCF7 cells. (D) The ligand-
activated  transcriptional activity
of AR was reduced in AR / 
MCF7 cells and abrogated in
AR /  MCF7 cells, compared
with  AR /  MCF7 cells. (E)
The proliferation of AR / 
MCF7 cells was reduced in
media containing 10% FBS (left)
or 10% CDS-FBS with ethanol
(e) or 10 10 M E2 (right), com-
pared with AR /  MCF7 cells,
using the MTT proliferation assay.
(F) The soft-agar colony formation
capacity of AR /  MCF7 cells
was largely reduced compared
with  AR /  MCF7 cells. (G)
AR siRNA efficiently knocked
down AR in the cells transfected
with np-AR. Full length of the 110-kD AR was detected by anti-AR antibody (NH27) using Western blotting assays. Cells were cotransfected with
pEGFP-C1 vector for normalization of transfection efficiency. GFP expression was detected with anti-GFP antibody. (H) The mRNA expression of
Ki67 and c-myc, but not Bcl-2, was reduced in AR /  MCF7 cells transfected with AR siRNA using electroporation, compared with the cells trans-
fected with vector alone. Electroporation was performed using 0.4-cm cuvettes and Gene Pulser II set at 280 V and 950  F.Yeh et al. 1905
(Fig. 5 G). These results are consistent with the data in Fig.
3 C showing that the ER target gene expression is reduced
in AR /  mouse breasts.
The NH2 Terminus/DNA-binding Domain (DBD) of AR Is
Required for MAPK Activation.  To further determine
which functional domain of AR is required to restore the
normal MAPK activity in AR /  MCF7 cells, various AR
fragments were reintroduced into AR /  MCF7 cells (Fig.
6 A). We found that the NH2 terminus together with DBD
(but not ligand-binding domain [LBD]), LBD with dele-
tion of helix 12 domain (LBD-dH12), DBD alone, or NH2
terminus alone can restore the MAPK activation (Fig. 6 A).
Next, because an AR mutant (AR-R608K) has been sug-
gested to be associated with male breast cancer (31), we
were interested to know its effect on the MAPK activation.
We found that in AR /  MCF7 cells, AR-R608K had a
higher induction fold on MAPK activation than AR-FL
(Fig. 6 B), suggesting that the contribution of AR-R608K
to breast cancer incidence may involve the excessive acti-
vation of MAPK. Next, the requirement of AR NH2 ter-
minus/DBD, but not LBD, to restore the MAPK activa-
tion was further confirmed by using a double mutation AR
(AR-R614H-dprm) with a deletion of the proline-rich
motif (dprm) at the NH2-terminal region (32) and a point
mutation on the second zinc-finger motif (R614H) at the
DBD (33). Although AR with a single mutation, AR-R614H
or AR-dprm, still partially retains the ability to activate
MAPK, the double mutation AR-R614H-dprm almost
loses the whole capacity to restore the MAPK activity,
even though these AR mutants contain intact LBDs (Fig. 6
B). Together, these restoration assays indicate that AR,
through its NH2 terminus/DBD domains, plays an impor-
tant role for the MAPK activation in MCF7 cells.
Discussion
Using three different approaches (Cre-lox conditional
KO, siRNA, and homologous recombination) to abrogate
the AR function in female mice and MCF7 breast cancer
cells, we demonstrate that AR may go through interrup-
tion of MAPK activity and ER signaling to exert its impor-
tant roles for the normal mouse mammary gland develop-
ment and MCF7 breast cancer cell growth. These results
are in agreement with early papers showing that both
MAPK and ER are essential factors for mammary gland de-
velopment and breast cancer growth. For example, female
ER /  mice exhibit undeveloped mammary glands similar
to those of newborn mice, indicating the essential roles of
ER in the ductal growth (21), and the loss of ER can sig-
nificantly delay the onset of tumor induction in MMTV-
Figure 5. AR was essential for
growth factor and estrogen sig-
naling pathway. (A) Growth
factor–induced cell proliferation
was impaired in AR /  MCF7
cells, compared with AR / 
MCF7 cells. Cultures were incu-
bated with RPMI 1640 media
containing 0.2% serum treated
with or without growth factors
for 8 d. (B) The steady-state
level of the active form of
MAPK was lower in AR / 
MCF7 cells than that in AR / 
MCF7 cells, when cells were
cultured in the media containing
1% HI-FBS for 5 d (left).
Growth factor–induced tran-
scriptional activity of GAL4-
Elk1 was diminished in AR / 
MCF7 cells (middle) and in
AR /  MCF7 cells transfected
with AR siRNA (right). (C)
The reduced MAPK activity was
restored by np-AR, which ex-
presses full-length AR and is
driven by natural AR promoter.
np-AR synergistically enhanced
EGF-induced GAL4-Elk1 trans-
activation. (D) The AR-FL–
activated  GAL4-Elk1 transacti-
vation can be inhibited by a
MAPK phosphatase (CL-100), a specific inhibitor U0126, dominant-negative Ras (Ras-DN), or Raf (Raf-DN). AR-FL, full-length WT AR. (E) Consti-
tutively activated MEK1 (MEK-CA), Ras (Ras-CA), or Raf (Raf-CA), but not Rac (Rac-CA) or PI3K (p110 catalytic subunit), can block the suppressive
effect of AR siRNA on the activity of GAL4-Elk1. (F) The transcriptional activity of ER is reduced in AR /  MCF7 cells, compared with AR / 
MCF7 cells. (G) The reduced ER activity in AR /  MCF7 cells was restored by np-AR. pG5-Luc and ERE-Luc were the reporters for GAL4-Elk1
and ER, respectively. pRL-TK was used as an internal control. Transfections were performed using SuperFect according to the manufacturer’s instructions.
Values shown are the mean   SD from at least four independent experiments.Androgen Receptor Roles in Mammary Glands 1906
Neu ( Neu/ER / ) or –Wnt-1 (Wnt-1/ER / ) transgenic
mice lacking functional ER (36, 37). The MAPK inhibitor
PD098059 could inhibit both the mammary gland alveolar
morphogenesis (20) and Her2/Neu-, H-Ras– or C-myc–ini-
tiated mammary tumor growth (38).
To dissect how AR influences MAPK activity, we found
that loss of AR could disrupt the IGF-I–, EGF-, and
HRG- –induced MAPK activity (Fig. 4 B) and reduced
IGF-IR expression in AR /  mice (Fig. 3 C). Bonnette et
al. (23) found that mice with defective IGF-IR have less
branching and decreased cellular proliferation of TEBs in
developing mammary glands, and these defects could be
only partly restored during pregnancy. Similar phenomena
also occurred in AR /  mice (Figs. 1 and 2), suggesting
that the suppression of IGF-IR by the AR abrogation may
contribute to the retarded mammary gland development in
AR /  mice. Consistent with data (Fig. 4 F and Fig. 5 B)
showing that the loss of AR interrupts HRG- –induced
anchorage-independent cell growth and MAPK activation,
Watson et al. (39) found that in transgenic rats with over-
expression of HER2–Neu in the mammary gland, normal
males, but not castrated males, developed mammary tu-
mors. These results may suggest the potential cross-talk be-
tween androgen–AR and HER2–Neu signaling pathways
in mammary tumor progression.
Further mechanism dissection studies indicate that AR-
induced MAPK activation is via the Ras/Raf/MAPK cas-
cade (Fig. 5 D), although the detailed mechanisms of how
AR influences Ras-Raf activity remain unclear. Migliaccio
et al. (32) reported that AR could activate MAPK via the in-
teraction between the proline-rich motif of AR and the
SH3 domain of c-Src. They demonstrated that this interac-
tion occurred quickly and could be initiated in a short time
by androgen or estrogen treatment. In contrast, Fig. 6 A
demonstrates that AR NH2 terminus/DBD, without the
LBD, can induce MAPK activity, suggesting that AR, but
not androgen, is the major factor to activate MAPK activity.
This raises an interesting question: what is the role of AR in
the breast cancer development? Early analyses of androgen–
AR roles in breast cancer mainly focused on the effect of an-
drogen treatment on the breast cancer showing that andro-
gen could either promote or suppress breast cancer growth
(5, 6, 40). On the other hand, the effect of AR protein itself
may also possibly go through interaction with other proteins
resulting in nongenomic and/or nonandrogenic activities. It
is likely that AR signals may use multiple pathways, includ-
ing the classic androgen/AR→AR target genes of genomic
actions as well as AR→AR interaction proteins of nonge-
nomic action to exert its roles in the breast cancer progres-
sion. This is in agreement with early papers showing that
ER could also cross-talk to MAPK in breast cancer cells (25,
41). In addition to estrogens, ER could be activated via
phosphorylation at Ser118 by MAPK to induce its target
gene expression (25). In return, ER could also induce the
Ras/Raf/MAPK cascade via nongenomic action (32).
Therefore, our results showing that AR could influence
both MAPK and ER signals suggest that the reduction of
ER activity could be due to the reduced MAPK activity,
and the reduced MAPK activity may be due to the reduced
ER activity in female mice and MCF7 cells lacking AR.
Figure 6. The NH2 terminus/
DBD of AR were required for
normal MAPK activation, and an
AR mutant (R608K) was associ-
ated with the excessive activation
of MAPK. (A) Ectopical expres-
sion of AR restored the defective
MAPK activity in AR /  MCF7
cells. The NH2 terminus together
with the DBD, but not N, DBD,
LBD, or LBD-dH12 alone, were
required for activating MAPK,
using a transient transfection assay
(middle) and a Western blot
(bottom) with anti–phospho-
MAPK and anti-MAPK antibod-
ies. All of the sequence constructs
were FLAG-tagged and inserted
into pCDNA3 vector. V, vector
alone. dH4–12, AR with dele-
tion from helix 4 to helix 12.
(B) The AR-R608K–induced
GAL4-Elk1 transactivation was
higher than AR-FL. AR-R614H-
dprm, containing a point mutation (R614H) and a dprm, lost the ability to activate MAPK, whereas AR-R614H or AR-dprm still partially retained
MAPK activation capacity. pG5-Luc was the reporter for GAL4-Elk1, and 5 ng/well pRL-TK was used for internal control. Values shown are mean  
SD from at least four independent experiments. (C) The proposed molecular mechanisms. The AR abrogation in mammary glands or mammary cancer
cells retards the growth or development via the impairments of the growth factor and ER signaling pathways. The reduced ER activity, as demonstrated
by the decreased target gene expression (Efp and HGF), may partly result from the impairment of the growth factors/MAPK signaling pathway. The
reduced PR activity may be due to the reduction of ER activity and/or the serum level of P after puberty but not before puberty (asterisk). The decreased
cyclin D1 expression may be caused by the impairments of both the growth factor/MAPK and ER signaling pathways. Together, these impaired signals
may contribute to the developmental defects of mouse mammary glands in AR /  mice and growth inhibition in breast cancer cells lacking AR.Yeh et al. 1907
In conclusion, this paper provides the first in vivo evi-
dence showing that AR may go through growth factors,
MAPK, and ER/PR signals (summary in Fig. 6 C) to con-
trol the normal breast development, and modulate the
breast cancer cell proliferation, especially in the conditions
of absence of or reduced E2 (Fig. 4 E). Whether this would
imply there is a positive correlation between AR expression
and breast cancer incidence/progression in women with
lower circulating E2, such as with the postmenopausal
stages, remains an interesting question for future study. Epi-
demiological papers support this correlation suggesting that
AR expression is more significantly associated with breast
cancer in postmenopausal women than premenopausal
women (9, 13, 42), and up to 50% of the AR-positive
breast cancers are ER- and/or PR-negative (13, 43). Fi-
nally, as AR NH2 terminus/DBD, but not LBD, may play
essential roles to modulate the growth factor signaling path-
ways in MCF7 breast cancer cells, targeting the function of
AR NH2 terminus/DBD may represent a new potential
therapeutic approach to the battle against breast cancer.
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